New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
10:01 EDTSUSQ, RAX, PBCT, MPET, LEJU, ICPT, ITW, GLRI, GSK, FCF, EBS, CHKE, CAMP, BDSI, ACADOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ACADIA (ACAD) initiated with an Overweight at JPMorgan... BioDelivery Sciences (BDSI) initiated with a Buy at Summer Street... CalAmp (CAMP) initiated with an Overweight at Stephens... Cherokee (CHKE) initiated with a Buy at B. Riley... Emergent BioSolutions (EBS) initiated with a Buy at Summer Street... First Commonwealth (FCF) initiated with a Neutral at SunTrust... GlaxoSmithKline (GSK) initiated with an Overweight at JPMorgan... Glori Energy (GLRI) initiated with a Buy at Maxim... Illinois Tool Works (ITW) reinstated with a Neutral at Credit Suisse... Intercept (ICPT) initiated with a Buy at Summer Street... Leju (LEJU) initiated with an Outperform at Macquarie... Magellan Petroleum (MPET) initiated with a Buy at B. Riley... People's United (PBCT) initiated with a Neutral at SunTrust... Rackspace (RAX) assumed with an Overweight at JPMorgan... Susquehanna (SUSQ) initiated with a Neutral at SunTrust.
News For ACAD;BDSI;CAMP;CHKE;EBS;FCF;GSK;GLRI;ITW;ICPT;LEJU;MPET;PBCT;RAX;SUSQ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 22, 2014
07:48 EDTGSKGlaxoSmithKline announces restructuring program for pharmaceuticals business
Subscribe for More Information
07:46 EDTGSKGlaxoSmithKline to explore IPO of minority shareholding in ViiV Healthcare
Glaxo announced "further significant steps" within its Pharmaceuticals business to realize value for shareholders and deliver improved operational performance. Glaxo stated: "Five years ago, we created ViiV Healthcare, a new standalone global business focused on development of treatments for HIV. This has been a highly innovative and successful venture with our equity partners Pfizer and Shionogi. The business has made very significant progress in both R&D and commercial execution, culminating in the recent successful launches of Tivicay and Triumeq. We believe now is the right time to explore the potential for an IPO of a minority shareholding in this business. This will provide greater visibility of the intrinsic value we see in its currently marketed assets and future pipeline and also enhance potential future strategic flexibility."
07:44 EDTGSKGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
07:42 EDTGSKGlaxoSmithKline reports Q3 core EPS 27.9p, up 5% CER ex-divestments
Subscribe for More Information
06:43 EDTICPTNASH market big enough for multiple players, says Deutsche Bank
Subscribe for More Information
06:41 EDTGSKWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
October 21, 2014
11:04 EDTGSKGlaxoSmithKline receives orphan status for dabrafenib
The FDA granted GlaxoSmithKline orphan status for dabrafenib, its possible treatment of patients with BRAF mutation positive non-small cell lung cancer.
08:07 EDTITWIllinois Tool Works raises FY14 EPS view to $4.57-$4.65 from $4.50-$4.62
Subscribe for More Information
08:07 EDTITWIllinois Tool Works sees Q4 EPS $1.07-$1.15, consensus $1.13
Sees Q4 revenue flat due to currency translation effects, consensus $3.64B.
08:04 EDTITWIllinois Tool Works reports Q3 EPS $1.28, consensus $1.23
Subscribe for More Information
07:06 EDTGSKFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
15:36 EDTITWNotable companies reporting before tomorrow's open
Subscribe for More Information
09:09 EDTGSKEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
08:10 EDTPBCTPeople's United downgraded at Raymond James
Subscribe for More Information
07:19 EDTGSKIBC Life Sciences to hold a conference
Subscribe for More Information
07:02 EDTPBCTPeople's United downgraded at Raymond James
As previously reported, Raymond James downgraded People's United to Market Perform from Outperform. The firm downgraded shares based on uncertainty regarding Fed tightening and recent declines in interest rates.
06:42 EDTPBCTPeople's United downgraded to Market Perform from Outperform at Raymond James
October 17, 2014
14:50 EDTGSK, EBSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
11:17 EDTGSKGSK says Ebola vaccine too late for current epidemic, BBC reports
Subscribe for More Information
05:57 EDTLEJULeju upgraded to Buy from Neutral at Goldman
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use